Tempus AI Expands Into Digital Pathology With Paige Acquisition

Tempus AI, Inc. (NASDAQ:TEM) stock is trading higher on Friday after acquiring Paige, an AI company specializing in digital pathology.  

Tempus is a technology company focused on adopting AI to advance precision medicine.

The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology.

Also Read: Tempus AI Raises Outlook, CEO Cites Faster-Than-Expected Growth And Improved Margins

Deal consideration of $81.25 million is being paid predominantly in Tempus common stock, as well as Tempus’ assumption of Paige’s remaining commitment under its existing Microsoft Azure cloud services agreement.

Founded in 2017, Paige has developed and deployed several AI applications, including the first FDA-cleared AI application in pathology, allowing researchers ...